



## WEBINAR

June 8<sup>th</sup> and 9<sup>th</sup>, 2022 15.00 to 18.00 CEST

## EXPERT WORKSHOP ON MONOCLONAL ANTIBODIES FOR AMR PATHOGENS

The <u>COMBINE project</u> is part of the IMI AMR Accelerator. COMBINE wants to address capability building questions regarding the optimization of preclinical and clinical studies in the development of antibiotics, vaccines and other therapies to tackle AMR pathogens.

Antibiotic resistance has created an imminent need for innovative approaches for prevention and therapy of nosocomial infections. Monoclonal antibodies (mAbs) are an increasingly promising strategy, but many hurdles in the development of these products remain. This free online workshop will provide an open discussion forum to identify and prioritize specific challenges and propose mitigation strategies to be implemented in future developments. Investigators from industry, academia, regulatory agencies and public health bodies working in preclinical or clinical development of mAbs for infectious diseases are invited to join. Please register (separately for each day) at the links below.

## Programme (all times in CEST):

Day 1. Wednesday, June 8 <sup>th</sup> Click here to register	Day 2. Thursday, June 9 <sup>th</sup> Click here to register
Motivation and focus on preclinical development and translation 15.00-15.10: Introduction	Focus on clinical and study design issues and mitigation strategies 15.00-15.10: Introduction
15.10-15.50: mAbs for AMR pathogens: where are we?	15.10-16.50: Focus on recurring problems in the clinical development
15.50-16.00: Biobreak 16.00-17.50: Focus on preclinical development and translation 17.50-18.00: Wrap up	16.50-17.00 Biobreak 17.00-17.50: Focus on mitigation strategies in the clinical development 17.50-18.00: Wrap up

Help us tailor the workshop to your needs by participating in this short survey!

For additional information, please contact imi-combine@pei.de.



www.amr-accelerator.eu





